Saturday 17 October 2026
Export KALA’s income statement to Excel — free account
KALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.
0.19
0.00
0.00%
Follow KALA
KALA BIO, Inc. (KALA) P/E ratio
KALA BIO, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 223× (July 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 223×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| OSRH OSR Health, Inc. compare | n/m |
| ERNA Ernexa Therapeutics Inc. compare | n/m |
| KALA KALA BIO, Inc. | n/m |
| IOBTQ IO Biotech, Inc. compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| LIPO Lipella Pharmaceuticals Inc. compare | n/m |
| UNBX UNITY Biotechnology, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)